MedTrace Logo

Radiation and Androgen Ablation for Prostate Cancer

NCT01517451 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-02-11

Study results available
· View outcomes & findings →

Summary

A study to see how effective and tolerable radiation therapy along with androgen deprivation therapy is in treating prostate cancer.

Conditions

  • Adenocarcinoma of the Prostate

Interventions

RADIATION

Radiation Therapy

7.25 Gy every other day fractions to a total dose of 36.25 Gy (total of 5 fractions)

DRUG

Androgen Deprivation Therapy (ADT)

Androgen deprivation therapy (ADT) for 4 months total, greater than or equal to 1 month prior to SBRT.

Sponsors & Collaborators

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    lead OTHER

Principal Investigators

  • Daniel Song, M.D. · Johns Hopkins University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-22
Primary Completion
2024-02-28
Completion
2025-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01517451 on ClinicalTrials.gov